JP6675985B2 - アルファ−ｔｅａ塩形態：疾患を処置するための組成物および使用 - Google Patents

アルファ−ｔｅａ塩形態：疾患を処置するための組成物および使用 Download PDF

Info

Publication number
JP6675985B2
JP6675985B2 JP2016540431A JP2016540431A JP6675985B2 JP 6675985 B2 JP6675985 B2 JP 6675985B2 JP 2016540431 A JP2016540431 A JP 2016540431A JP 2016540431 A JP2016540431 A JP 2016540431A JP 6675985 B2 JP6675985 B2 JP 6675985B2
Authority
JP
Japan
Prior art keywords
compound
cancer
salt
polymorphic form
tea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016540431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532714A5 (enExample
JP2016532714A (ja
Inventor
マイケル オニール
マイケル オニール
バーバラ キドン
バーバラ キドン
トーマス アドキンス
トーマス アドキンス
ホンキャオ ウー
ホンキャオ ウー
エマニュエル ティー． アクポリアイエ
エマニュエル ティー． アクポリアイエ
Original Assignee
リサーチ ディベロップメント ファウンデーション
リサーチ ディベロップメント ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ ディベロップメント ファウンデーション, リサーチ ディベロップメント ファウンデーション filed Critical リサーチ ディベロップメント ファウンデーション
Publication of JP2016532714A publication Critical patent/JP2016532714A/ja
Publication of JP2016532714A5 publication Critical patent/JP2016532714A5/ja
Application granted granted Critical
Publication of JP6675985B2 publication Critical patent/JP6675985B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016540431A 2013-09-06 2014-09-05 アルファ−ｔｅａ塩形態：疾患を処置するための組成物および使用 Active JP6675985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874823P 2013-09-06 2013-09-06
US61/874,823 2013-09-06
PCT/US2014/054354 WO2015035212A1 (en) 2013-09-06 2014-09-05 Alpha-tea salt forms: compositions and uses for treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019231273A Division JP2020063294A (ja) 2013-09-06 2019-12-23 アルファ−ｔｅａ塩形態：疾患を処置するための組成物および使用

Publications (3)

Publication Number Publication Date
JP2016532714A JP2016532714A (ja) 2016-10-20
JP2016532714A5 JP2016532714A5 (enExample) 2017-10-12
JP6675985B2 true JP6675985B2 (ja) 2020-04-08

Family

ID=51570908

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016540431A Active JP6675985B2 (ja) 2013-09-06 2014-09-05 アルファ−ｔｅａ塩形態：疾患を処置するための組成物および使用
JP2019231273A Pending JP2020063294A (ja) 2013-09-06 2019-12-23 アルファ−ｔｅａ塩形態：疾患を処置するための組成物および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019231273A Pending JP2020063294A (ja) 2013-09-06 2019-12-23 アルファ−ｔｅａ塩形態：疾患を処置するための組成物および使用

Country Status (9)

Country Link
US (2) US10370350B2 (enExample)
EP (1) EP3041831B1 (enExample)
JP (2) JP6675985B2 (enExample)
AU (1) AU2014318014C1 (enExample)
CA (1) CA2922375C (enExample)
DK (1) DK3041831T3 (enExample)
ES (1) ES2766324T3 (enExample)
PL (1) PL3041831T3 (enExample)
WO (1) WO2015035212A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014318014C1 (en) 2013-09-06 2018-11-15 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
CN107050432B (zh) * 2017-02-28 2019-09-10 上海交通大学医学院 胃泌素在制备诊断和治疗乳腺癌药物中的应用
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
EP3646873A1 (en) * 2018-10-31 2020-05-06 Aprofol AG Folate salts
CN111635390A (zh) * 2020-06-30 2020-09-08 江南大学 一种低泡型α-生育酚表面活性剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4629734Y1 (enExample) 1968-04-23 1971-10-14
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
JP2634047B2 (ja) * 1985-10-15 1997-07-23 ザ リポソ−ム カンパニ−，インコ−ポレイテツド アルファトコフェロールをベースとした小胞体
US6770672B1 (en) 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
AU2001236805B2 (en) 2000-02-11 2005-07-14 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
ATE468109T1 (de) * 2001-12-19 2010-06-15 Res Dev Foundation Liposomale abgabe von verbindungen auf vitamin-e- basis
AU2014318014C1 (en) 2013-09-06 2018-11-15 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease

Also Published As

Publication number Publication date
DK3041831T3 (da) 2020-01-27
ES2766324T3 (es) 2020-06-12
CA2922375A1 (en) 2015-03-12
US20200148661A1 (en) 2020-05-14
JP2020063294A (ja) 2020-04-23
AU2014318014A1 (en) 2016-03-17
EP3041831A1 (en) 2016-07-13
JP2016532714A (ja) 2016-10-20
AU2014318014C1 (en) 2018-11-15
US10370350B2 (en) 2019-08-06
US10934267B2 (en) 2021-03-02
US20160214954A1 (en) 2016-07-28
WO2015035212A1 (en) 2015-03-12
EP3041831B1 (en) 2019-10-23
CA2922375C (en) 2021-06-15
PL3041831T3 (pl) 2021-07-19
AU2014318014B2 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
JP2020063294A (ja) アルファ−ｔｅａ塩形態：疾患を処置するための組成物および使用
JP2022140637A (ja) 結晶性（８Ｓ，９Ｒ）－５－フルオロ－８－（４－フルオロフェニル）－９－（１－メチル－１Ｈ－１，２，４－トリアゾール－５－イル）－８，９－ジヒドロ－２Ｈ－ピリド［４，３，２－ｄｅ］フタラジン－３（７Ｈ）－オントシレート塩
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
ES2988672T3 (es) Formas sólidas de ursodesoxicolato de berberina y composiciones y métodos de las mismas
CA3035697A1 (en) Biaryl compounds useful as immunomodulators
AU2017363313A1 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
TWI557125B (zh) 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法
KR20200019226A (ko) 약학 조성물
CN111018846B (zh) 化合物晶型
AU2017221422A1 (en) MAX binders as Myc modulators and uses thereof
EP4249072A2 (en) Crystalline forms of quinolone analogs and their salts
US12479808B2 (en) Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
WO2017198194A1 (zh) 一种硼酸和硼酸酯类化合物及其应用
ES2967517T3 (es) Sales de niraparib
WO2023107966A1 (en) Salt and solid forms of lysergic acid diethylamide (lsd) and analogs
CN112888698A (zh) 2’-卤代-4’-硫代-2’-脱氧-5-氮杂胞苷类似物及其使用方法
AU2019318046A1 (en) Histone demethylase 5 inhibitors and uses thereof
CN107954946B (zh) 酚噻嗪化合物及其用途
CN114096522A (zh) 化合物的晶型和制备化合物的晶型的方法
WO2011147254A1 (zh) 苯丁酰基姜黄素衍生物及其在制备抗肿瘤药物中的应用
JP2018527372A (ja) 副溝結合テイルを有するｄｎａ結合物質
CN120757534A (zh) 喹唑林类化合物及其用途
WO2025158077A1 (en) Lipid degraders to trigger ferroptosis in cancer
JP2013518889A (ja) （Ｓ）−１−（４−（５−シクロプロピル−１Ｈ−ピラゾール−３−イルアミノ）ピロロ［１，２−ｆ］［１，２，４］トリアジン−２−イル）−Ｎ−（６−フルオロピリジン−３−イル）−２−メチルピロリジン−２−カルボキサミドの結晶形
HK40011956B (en) Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190329

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191223

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200311

R150 Certificate of patent or registration of utility model

Ref document number: 6675985

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250